- Home
- INKT vs BOLT Comparison
INKT vs BOLT Comparison
Compare INKT & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- BOLT
- Stock Information
- Founded
- INKT 2017
- BOLT 2015
- Country
- INKT United States
- BOLT United States
- Employees
- INKT N/A
- BOLT N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- INKT Health Care
- BOLT Health Care
- Exchange
- INKT Nasdaq
- BOLT Nasdaq
- Market Cap
- INKT 36.7M
- BOLT 22.6M
- IPO Year
- INKT 2021
- BOLT 2021
- Fundamental
- Price
- INKT $7.66
- BOLT $0.41
- Analyst Decision
- INKT Strong Buy
- BOLT Hold
- Analyst Count
- INKT 2
- BOLT 5
- Target Price
- INKT $19.50
- BOLT $1.25
- AVG Volume (30 Days)
- INKT 11.7K
- BOLT 101.5K
- Earning Date
- INKT 03-18-2025
- BOLT 03-20-2025
- Dividend Yield
- INKT N/A
- BOLT N/A
- EPS Growth
- INKT N/A
- BOLT N/A
- EPS
- INKT N/A
- BOLT N/A
- Revenue
- INKT N/A
- BOLT $9,779,000.00
- Revenue This Year
- INKT N/A
- BOLT $9.87
- Revenue Next Year
- INKT N/A
- BOLT N/A
- P/E Ratio
- INKT N/A
- BOLT N/A
- Revenue Growth
- INKT N/A
- BOLT 35.86
- 52 Week Low
- INKT $4.56
- BOLT $0.42
- 52 Week High
- INKT $19.00
- BOLT $1.56
- Technical
- Relative Strength Index (RSI)
- INKT 40.33
- BOLT 31.42
- Support Level
- INKT $7.90
- BOLT $0.42
- Resistance Level
- INKT $8.88
- BOLT $0.48
- Average True Range (ATR)
- INKT 0.85
- BOLT 0.03
- MACD
- INKT -0.27
- BOLT -0.00
- Stochastic Oscillator
- INKT 2.69
- BOLT 0.00
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.